Belvedere Trading’s Axsome Therapeutics AXSM Stock Holding History

Belvedere Trading’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$15.4K	–	941
2022 Q4	$15.4K	Buy	+200	New	+$12K	﹤0.01%	861

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's AXSM Position: Q1 2023 in Review

Belvedere Trading sold out of Axsome Therapeutics (AXSM) in Q1 2023, closing a stake of 2,119 shares — an estimated $163K sold.

Belvedere Trading first reported a position in AXSM in Q3 2021 and held it in 2 quarters. The position peaked at $902K in Q3 2021. 197 funds tracked by Wall St. Rank hold AXSM as of Q1 2023.

Belvedere Trading reported no remaining Axsome Therapeutics position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 2,119 Axsome Therapeutics shares in Q1 2023, an estimated $163K.
Belvedere Trading first reported a position in Axsome Therapeutics in Q3 2021 and held it in 2 quarters.
Belvedere Trading's Axsome Therapeutics position peaked at $902K in Q3 2021.
197 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.